Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting

Aim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) formedical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF. This study evaluates the cost–effectiveness and budget im...

Full description

Saved in:
Bibliographic Details
Main Authors: Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-05-01
Series:Journal of Comparative Effectiveness Research
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!